GSK reaches confidential settlement with David Browne in Zantac case

GSK plc (LON/NYSE:GSK) has confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court. This case was set to go to trial on 20 February 2024, and instead will now be dismissed.

The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case.

GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

Share on:

You might also enjoy reading GSK plc (GSK) Stock Analysis: Unlocking a 3.25% Potential Upside Amid Strong Dividend Yields

Written by: Amilia Stone

Latest Company News

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

December 12, 2025

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026.

GSK receives US FDA Orphan Drug Designation for SCLC treatment risvutatug rezetecan

December 10, 2025

GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has been granted Orphan Drug Designation by the US FDA for small-cell lung cancer.

GSK subsidiary TESARO starts legal action over Jemperli licence dispute

November 21, 2025

TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement for the cancer treatment Jemperli.

GSK Plc lifts 2025 guidance after strong Q3 sales and profit growth

October 29, 2025

GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.

GSK receives EMA Orphan Drug Designation for GSK5764227 in Pulmonary NEC

October 28, 2025

GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer.

GSK Plc gains FDA approval for Blenrep combination in multiple myeloma

October 24, 2025

GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies.